Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Know Labs Inc (OP: KNWN )

0.0850 -0.0070 (-7.61%)
Streaming Delayed Price Updated: 3:36 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 706,039
Open 0.0920
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0920
Today's Range 0.0810 - 0.0990
52wk Range 0.0240 - 0.1398
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Know Labs, Inc. to Report First Quarter FY 2025 Results
From Know Labs, Inc.
Via Business Wire
Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2025 Results on February 14, 2025
From Know Labs, Inc.
Via Business Wire

Performance

YTD
+7.73%
+7.73%
1 Month
+7.73%
+7.73%
3 Month
+7.73%
+7.73%
6 Month
+7.73%
+7.73%
1 Year
+7.73%
+7.73%

More News

Read More
Know Labs Technology Licensing (KTL) Announces Formalized Client Engagement
From Know Labs, Inc.
Via Business Wire
Know Labs Files Appeal to NYSE Commencement of Proceedings to Delist
From Know Labs, Inc.
Via Business Wire
The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group's Most-Active List In October
Via Benzinga
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
Via Benzinga
Know Labs, Inc. Announces NYSE American Listing Approval
From Know Labs, Inc.
Via Business Wire
Know Labs Provides Update on IRB-Approved Internal Trial of Non-Invasive Glucose Monitoring Technology
From Know Labs, Inc.
Via Business Wire
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Via News Direct
Exposures Product Safety
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Via TheNewswire.com
Exposures Product Safety
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Via Benzinga
This Company Reports Moving Toward FDA Approval To Provide Pain-Free Diabetes Monitoring
Via Benzinga
Know Labs Files S-1 for New Share Offering, Seeks Uplist to NYSE American Exchange
From Know Labs, Inc.
Via Business Wire
Can Artificial Intelligence Predict Our Future Health?
Via Benzinga
Comparing Fitbits To Medical Devices? This Company Says Things Aren't Even Close
Via Benzinga
Relief May Soon Be On The Way For Diabetes Sufferers Weary Of Constant Pin Pricks, According To This Company
Via Benzinga
Know Labs Expands Leadership Team, Adds Chief Financial Officer and Chief Product Officer, As It Gets Closer to FDA Clearance Application
From Know Labs, Inc.
Via Business Wire
Know Labs, Inc. Discusses Significance of Patented Non-Invasive Blood Glucose Monitoring Technology with The Stock Day Podcast
Via Newsfile
Exposures Product Safety
New Foundational Patents Secure Multiple Growth Opportunities for Know Labs and Its Bio-RFID™ Non-Invasive Diagnostic Technology
From Know Labs, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2022
Via Benzinga
Know Labs Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™
From Know Labs, Inc.
Via Business Wire
Insiders Buying Pixelworks And 4 Other Penny Stocks
Via Benzinga
Know Labs Launches Subsidiary, AI Mind Inc., Generates $4.2M in NFT Revenue to Fund Continued Non-Invasive Glucose Monitoring Device Development
From Know Labs, Inc.
Via Business Wire
New Test Data Confirm Particle™ Bulb from Know Labs Successfully Inactivates SARS-CoV-2 Variants
From Know Labs, Inc.
Via Business Wire
New Tests Show Know Labs Bio-RFID™ Technology Delivers Blood Glucose Readings Comparable to FDA-Cleared Devices
From Know Labs, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.